TY - JOUR
T1 - Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)
AU - Pemmaraju, Naveen
AU - Mesa, Ruben
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2015/12/5
Y1 - 2015/12/5
N2 - A 69-year-old man presents with a Dynamic International Prognostic Scoring System (DiPSS) intermediate-risk 2 post polycythemia vera myelofibrosis with significant splenomegaly, 30 pound weight loss, constitutional symptoms, and 2% peripheral blood blasts. He has no other significant past medical history and no other major comorbid conditions. You are asked by the hematology fellow you are supervising whether or not treating this patient with a Janus kinase (JAK) inhibitor will decrease major morbid events.
AB - A 69-year-old man presents with a Dynamic International Prognostic Scoring System (DiPSS) intermediate-risk 2 post polycythemia vera myelofibrosis with significant splenomegaly, 30 pound weight loss, constitutional symptoms, and 2% peripheral blood blasts. He has no other significant past medical history and no other major comorbid conditions. You are asked by the hematology fellow you are supervising whether or not treating this patient with a Janus kinase (JAK) inhibitor will decrease major morbid events.
UR - http://www.scopus.com/inward/record.url?scp=85010930959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010930959&partnerID=8YFLogxK
U2 - 10.1182/asheducation-2015.1.649
DO - 10.1182/asheducation-2015.1.649
M3 - Review article
C2 - 26637784
AN - SCOPUS:85010930959
SN - 1520-4391
VL - 2015
SP - 649
EP - 651
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -